Guarino Matteo, Costanzini Anna, Luppi Francesco, Maritati Martina, Contini Carlo, De Giorgio Roberto, Spampinato Michele Domenico
Department of Translational Medicine, St. Anna University Hospital of Ferrara, University of Ferrara, 44124 Ferrara, Italy.
Emergency Department, St. Anna University Hospital of Ferrara, 44124 Ferrara, Italy.
Biomedicines. 2025 Jul 9;13(7):1684. doi: 10.3390/biomedicines13071684.
: Sepsis and septic shock are major contributors to global morbidity and mortality. The "cytokine storm," a hyper-inflammatory response, plays a central role in sepsis pathophysiology, leading to multi-organ failure. Extracorporeal cytokine adsorption therapies, such as CytoSorb, Toraymyxin, Oxiris, HA330/380, and Seraph 100 Microbind, aim to mitigate the inflammatory response by removing circulating cytokines and other mediators. : A comprehensive search of Scopus and PubMed was conducted for studies published from January 2020 to May 2025. The search terms included "sepsis," "septic shock," and "extracorporeal cytokine adsorption." Relevant studies, including clinical trials and meta-analyses, were included to assess the efficacy and safety of these therapies. : Extracorporeal cytokine adsorption has shown promising results in reducing cytokine levels, improving organ function, and decreasing vasopressor requirements. However, evidence regarding mortality reduction remains inconsistent. Studies have demonstrated benefits in sepsis, ARDS, and cardiogenic shock, improving organ recovery and inflammatory markers. : Extracorporeal cytokine adsorption is a potential adjunctive therapy in sepsis management, offering improvements in organ function and inflammatory control. While the mortality benefit remains uncertain, ongoing research and large-scale clinical trials are essential to define its clinical role and optimize its application.
脓毒症和脓毒性休克是全球发病和死亡的主要原因。“细胞因子风暴”，一种过度炎症反应，在脓毒症病理生理学中起核心作用，导致多器官功能衰竭。体外细胞因子吸附疗法，如CytoSorb、Toraymyxin、Oxiris、HA330/380和Seraph 100 Microbind，旨在通过清除循环中的细胞因子和其他介质来减轻炎症反应。
对Scopus和PubMed进行了全面检索，以查找2020年1月至2025年5月发表的研究。检索词包括“脓毒症”、“脓毒性休克”和“体外细胞因子吸附”。纳入了相关研究，包括临床试验和荟萃分析，以评估这些疗法的疗效和安全性。
体外细胞因子吸附在降低细胞因子水平、改善器官功能和减少血管升压药需求方面已显示出有前景的结果。然而，关于降低死亡率的证据仍然不一致。研究已证明在脓毒症、急性呼吸窘迫综合征和心源性休克中有益，可改善器官恢复和炎症标志物。
体外细胞因子吸附是脓毒症管理中的一种潜在辅助疗法，可改善器官功能和炎症控制。虽然死亡率获益仍不确定，但正在进行的研究和大规模临床试验对于确定其临床作用和优化其应用至关重要。
